NO327210B1 - Farmasoytisk sett for behandling av infertilitet. - Google Patents
Farmasoytisk sett for behandling av infertilitet. Download PDFInfo
- Publication number
- NO327210B1 NO327210B1 NO20014736A NO20014736A NO327210B1 NO 327210 B1 NO327210 B1 NO 327210B1 NO 20014736 A NO20014736 A NO 20014736A NO 20014736 A NO20014736 A NO 20014736A NO 327210 B1 NO327210 B1 NO 327210B1
- Authority
- NO
- Norway
- Prior art keywords
- programming
- set according
- progestogen
- ovarian stimulation
- carried out
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 13
- 208000000509 infertility Diseases 0.000 title claims description 5
- 230000036512 infertility Effects 0.000 title claims description 5
- 231100000535 infertility Toxicity 0.000 title claims description 5
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims description 31
- 230000000638 stimulation Effects 0.000 claims description 30
- 230000002611 ovarian Effects 0.000 claims description 24
- 210000000287 oocyte Anatomy 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 16
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 15
- 239000000583 progesterone congener Substances 0.000 claims description 14
- 108700008462 cetrorelix Proteins 0.000 claims description 12
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 12
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 12
- 230000027758 ovulation cycle Effects 0.000 claims description 12
- 102000006771 Gonadotropins Human genes 0.000 claims description 10
- 108010086677 Gonadotropins Proteins 0.000 claims description 10
- 239000002622 gonadotropin Substances 0.000 claims description 10
- 230000001850 reproductive effect Effects 0.000 claims description 10
- 229940127234 oral contraceptive Drugs 0.000 claims description 9
- 239000003539 oral contraceptive agent Substances 0.000 claims description 9
- 230000004720 fertilization Effects 0.000 claims description 8
- 229960003230 cetrorelix Drugs 0.000 claims description 7
- 239000003433 contraceptive agent Substances 0.000 claims description 7
- 206010068042 Premature ovulation Diseases 0.000 claims description 6
- 230000002254 contraceptive effect Effects 0.000 claims description 6
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 6
- 229940094892 gonadotropins Drugs 0.000 claims description 6
- 230000016087 ovulation Effects 0.000 claims description 6
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 5
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 5
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 5
- 229940046836 anti-estrogen Drugs 0.000 claims description 5
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 5
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims description 5
- 229960003608 clomifene Drugs 0.000 claims description 5
- 239000000328 estrogen antagonist Substances 0.000 claims description 5
- 229960003794 ganirelix Drugs 0.000 claims description 5
- 108700032141 ganirelix Proteins 0.000 claims description 5
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 230000029849 luteinization Effects 0.000 claims description 5
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 229960002568 ethinylestradiol Drugs 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 3
- 108010023617 abarelix Proteins 0.000 claims description 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 3
- 229960002184 abarelix Drugs 0.000 claims description 3
- 108010070670 antarelix Proteins 0.000 claims description 3
- -1 antid Proteins 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 229950011372 teverelix Drugs 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 230000009027 insemination Effects 0.000 claims description 2
- 230000002175 menstrual effect Effects 0.000 claims description 2
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 2
- 229960001390 mestranol Drugs 0.000 claims description 2
- 210000002394 ovarian follicle Anatomy 0.000 claims description 2
- 230000011599 ovarian follicle development Effects 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 230000002051 biphasic effect Effects 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 6
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
- 108010057021 Menotropins Proteins 0.000 description 5
- 229940112106 cetrotide Drugs 0.000 description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 description 5
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 5
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 4
- 108010006578 follitropin alfa Proteins 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- 229940057854 gonal f Drugs 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033157 Ovarian enlargement Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12724199P | 1999-03-31 | 1999-03-31 | |
| US13163299P | 1999-04-28 | 1999-04-28 | |
| PCT/EP2000/002466 WO2000059542A1 (en) | 1999-03-31 | 2000-03-21 | Method for a programmed controlled ovarian stimulation protocol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20014736D0 NO20014736D0 (no) | 2001-09-28 |
| NO20014736L NO20014736L (no) | 2001-11-26 |
| NO327210B1 true NO327210B1 (no) | 2009-05-11 |
Family
ID=26825471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20014736A NO327210B1 (no) | 1999-03-31 | 2001-09-28 | Farmasoytisk sett for behandling av infertilitet. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8173592B1 (ja) |
| EP (1) | EP1165138B1 (ja) |
| JP (1) | JP4616999B2 (ja) |
| KR (1) | KR100679880B1 (ja) |
| CN (1) | CN1346281B (ja) |
| AR (1) | AR023249A1 (ja) |
| AT (1) | ATE265862T1 (ja) |
| AU (1) | AU768544B2 (ja) |
| BG (1) | BG65270B1 (ja) |
| BR (1) | BR0009477A (ja) |
| CA (1) | CA2367214C (ja) |
| CO (1) | CO4970741A1 (ja) |
| CZ (1) | CZ299820B6 (ja) |
| DE (1) | DE60010452T2 (ja) |
| DK (1) | DK1165138T3 (ja) |
| ES (1) | ES2219331T3 (ja) |
| HK (1) | HK1044892B (ja) |
| HU (1) | HU229252B1 (ja) |
| IL (2) | IL145630A0 (ja) |
| MX (1) | MXPA01009862A (ja) |
| NO (1) | NO327210B1 (ja) |
| NZ (1) | NZ514964A (ja) |
| PL (1) | PL199569B1 (ja) |
| PT (1) | PT1165138E (ja) |
| RU (1) | RU2226395C2 (ja) |
| SK (1) | SK287244B6 (ja) |
| TW (1) | TWI241194B (ja) |
| WO (1) | WO2000059542A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0788799A3 (en) | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| PL219030B1 (pl) | 2003-02-21 | 2015-03-31 | Schering Ag | Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV |
| US8668925B2 (en) | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| EP1719504A1 (de) * | 2005-05-02 | 2006-11-08 | Schering AG | Festes transdermales therapeutisches System mit UV-Absorber |
| US8962013B2 (en) * | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| AU2006270749B2 (en) * | 2005-07-22 | 2013-02-07 | Takeda Pharmaceutical Company Limited | Premature ovulation preventive agent |
| DK2916914T3 (da) * | 2012-11-09 | 2017-01-02 | Iasomai Ab | N-acetyl-L-cystein til anvendelse i in vitro befrugtning |
| EP3194581A4 (en) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
| JP7079094B2 (ja) | 2015-04-17 | 2022-06-01 | フェリング ベスローテン フェンノートシャップ | 不妊症の処置のための組成物 |
| MA46353A (fr) * | 2016-09-30 | 2019-08-07 | Myovant Sciences Gmbh | Méthodes de traitement de l'infertilité féminine |
| RU2665967C1 (ru) * | 2017-06-14 | 2018-09-05 | Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) | Способ стимуляции роста фолликулов в программах экстракорпорального оплодотворения у пациенток с бесплодием различного генеза и "бедным ответом на стимуляцию" |
| CN107982520A (zh) * | 2017-12-25 | 2018-05-04 | 上海交通大学医学院附属第九人民医院 | 外源性MPA与hMG在制备动物模型药物中的应用 |
| CN110570952B (zh) * | 2018-06-05 | 2022-04-12 | 北京大学第三医院 | 预测拮抗剂方案下受试者卵巢低反应概率的系统及指导促性腺激素起始用药剂量选择的系统 |
| CN110491505B (zh) * | 2019-08-22 | 2021-06-01 | 北京大学第三医院（北京大学第三临床医学院） | 预测受试者卵巢刺激过程中获得的卵母细胞数量的系统 |
| CN113456801A (zh) * | 2021-08-05 | 2021-10-01 | 浙江大学医学院附属第四医院 | 人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4016259A (en) * | 1974-07-26 | 1977-04-05 | Research Corporation | Contraceptive polypeptides |
| EP0161063B1 (en) * | 1984-04-03 | 1991-07-24 | Serono Laboratories, Inc. | Method of inducing ovulation |
| DE69022722T2 (de) | 1989-03-10 | 1996-05-02 | Endorecherche Inc., Ste-Foy, Quebec | Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen. |
| US5470847A (en) * | 1993-12-10 | 1995-11-28 | Board Of Regents, The University Of Texas System | Ovulation control by regulating nitric oxide levels with arginine derivatives |
| DE69515666T2 (de) | 1994-07-22 | 2000-07-06 | Hampton Roads Medical College | VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN |
| EP0788799A3 (en) * | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| US5945128A (en) * | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
| CA2200541C (en) | 1997-01-22 | 2013-02-19 | Philippe Bouchard | Lhrh-antagonists in the treatment of fertility disorders |
| AU4325797A (en) * | 1997-06-23 | 1999-01-04 | Mcneil-Ppc, Inc. | Acetaminophen and cisapride analgesics |
| AU752415B2 (en) * | 1998-04-23 | 2002-09-19 | Zentaris Ivf Gmbh | Method for the treatment of fertility disorders |
-
2000
- 2000-03-10 US US09/523,455 patent/US8173592B1/en not_active Expired - Fee Related
- 2000-03-21 AT AT00920521T patent/ATE265862T1/de active
- 2000-03-21 AU AU41069/00A patent/AU768544B2/en not_active Expired
- 2000-03-21 PL PL351327A patent/PL199569B1/pl unknown
- 2000-03-21 HU HU0200431A patent/HU229252B1/hu unknown
- 2000-03-21 KR KR1020017012422A patent/KR100679880B1/ko active IP Right Grant
- 2000-03-21 CA CA002367214A patent/CA2367214C/en not_active Expired - Lifetime
- 2000-03-21 WO PCT/EP2000/002466 patent/WO2000059542A1/en active IP Right Grant
- 2000-03-21 RU RU2001129500/14A patent/RU2226395C2/ru active
- 2000-03-21 ES ES00920521T patent/ES2219331T3/es not_active Expired - Lifetime
- 2000-03-21 CZ CZ20013495A patent/CZ299820B6/cs not_active IP Right Cessation
- 2000-03-21 JP JP2000609104A patent/JP4616999B2/ja not_active Expired - Lifetime
- 2000-03-21 DE DE60010452T patent/DE60010452T2/de not_active Expired - Lifetime
- 2000-03-21 SK SK1384-2001A patent/SK287244B6/sk not_active IP Right Cessation
- 2000-03-21 EP EP00920521A patent/EP1165138B1/en not_active Expired - Lifetime
- 2000-03-21 NZ NZ514964A patent/NZ514964A/en not_active IP Right Cessation
- 2000-03-21 CN CN008059632A patent/CN1346281B/zh not_active Expired - Lifetime
- 2000-03-21 MX MXPA01009862A patent/MXPA01009862A/es active IP Right Grant
- 2000-03-21 BR BR0009477-3A patent/BR0009477A/pt not_active Application Discontinuation
- 2000-03-21 DK DK00920521T patent/DK1165138T3/da active
- 2000-03-21 PT PT00920521T patent/PT1165138E/pt unknown
- 2000-03-21 IL IL14563000A patent/IL145630A0/xx unknown
- 2000-03-27 TW TW089105594A patent/TWI241194B/zh not_active IP Right Cessation
- 2000-03-29 CO CO00022260A patent/CO4970741A1/es unknown
- 2000-03-31 AR ARP000101492A patent/AR023249A1/es not_active Application Discontinuation
-
2001
- 2001-09-25 IL IL145630A patent/IL145630A/en not_active IP Right Cessation
- 2001-09-28 NO NO20014736A patent/NO327210B1/no not_active IP Right Cessation
- 2001-10-24 BG BG106045A patent/BG65270B1/bg unknown
-
2002
- 2002-08-23 HK HK02106205.6A patent/HK1044892B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serhal et al. | Ovum donation—a simplified approach | |
| EP1165138B1 (en) | Programmed controlled ovarian stimulation protocol using oral contraceptives | |
| Melis et al. | Ovulation induction with gonadotropins as sole treatment in infertile couples with open tubes: a randomized prospective comparison between intrauterine insemination and timed vaginal intercourse | |
| Sengoku et al. | Endocrinology: A randomized prospective study of gonadotrophin with or without gonadotrophin-releasing hormone agonist for treatment of unexplained infertility | |
| Chang et al. | No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist | |
| Roulier et al. | Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment | |
| JP2002541122A5 (ja) | ||
| EP1455831B1 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| US7393834B2 (en) | LHRH-antagonists in the treatment of fertility disorders | |
| JP2003520823A5 (ja) | ||
| Sauer et al. | A trial of superovulation in ovum donors undergoing uterine lavage | |
| Gerli et al. | Programming of ovarian stimulation with norethindrone acetate in IVF/GIFT cycles | |
| Isherwood et al. | Endocrine changes in women conceiving during treatment with an LHRH agonist | |
| Meldrum et al. | A pilot study to assess oral contraceptive (OC) pretreatment in women undergoing controlled ovarian hyperstimulation (COH) in ganirelix acetate cycles | |
| CA2200541C (en) | Lhrh-antagonists in the treatment of fertility disorders | |
| Nagori et al. | 6 Intrauterine Insemination | |
| EP1364658A1 (en) | Use of varying ratios of gonadotrophins in controlled ovarian hyperstimulation | |
| Trevisi et al. | Clomiphene Citrate in Poor Responder Patients Undergoing an ART: An Alternative to Gonadotropin? | |
| Brinsden | Superovulation strategies in assisted | |
| Malik et al. | Manual of |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |